Health
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced new real-world preliminary data from the OPTION-VMS Phase IV, longitudinal, observational study, providing the first insights into the real-world use of fezolinetant. The data demonstrated statistically significant improvements in VMS bother related to menopause, statistically significant improvements in subjective and objective sleep outcomes and significant improvements in activity impairment includi
About this update from Astellas Pharma Inc.
[{"type":"text","content":"Extensive and growing evidence continues to reinforce fezolinetant as an effective treatment for moderate to severe VMS associated with menopause","length":145,"tagName":"p","attribs":{}},{"type":"text","content":"Preliminary analysis from OPTION-VMS observational study demonstrated fezolinetant leads to statistically significant improvements in subjective and objective sleep outcomes","length":174,"tagName":"p","attribs":{}},{"type":"text","content":"Further analysis of work productivity outcomes indicate fezolinetant leads to statistically significant improvements in activity impairment, overall work productivity loss and presenteeism","length":189,"tagName":"p","attribs":{}},{"type":"text","content":"TOKYO, Oct. 22, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced new real-world preliminary data from the OPTION-VMS Phase IV, longitudinal, observational study, providing the first insights into the real-world use of fezolinetant. The data demonstrated statistically significant improvements in VMS bother related to menopause, statistically significant improvements in subjective and objective sleep outcomes and significant improvements in activity impairment including overall work productivity. VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause.1,2 These preliminary data will be presented this week as late-breaker poster presentations at The Menopause Society 2025 Annual Meeting (October 21-25) in Orlando, Florida.","length":855,"tagName":"p"},{"type":"image","alt":"Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)","displaySize":"","headline":null,"caption":"Astellas stands on the forefront of healthcare change to turn innovative science into value for patients.(PRNewsFoto/Astellas Pharma Inc.) (PRNewsfoto/Astellas Pharma Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":110,"url":"https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab05cc0666e5cfd53b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gt2H1Ajgjzgw_owZJZe3uA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2ea847d4f0afcbab0...